U.S. Markets closed

A Reverse Split and Key Demand Drivers for InspireMD's Proprietary Technology

NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuinga comprehensive report on InspireMD, Inc. (NSPR), a biotechnology company that has developed a portfolio of medical device assets using a proprietary technology called MicroNet. It's an alternative construction of a traditional stent, which removes some of the blockage risk associated with the current standard of care devices in the space.

CGuard EPS is the company's lead product, and it's a highly differentiated, minimally invasive treatment for carotid artery disease designed around its proprietary and elegantly simple MicroNet technology to dramatically reduce or even eliminate the incidence of stroke following carotid artery procedures.

Get details of the recent reverse split, info on CGuard market development and more READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/inspiremd/

At LINC 2019, interim data from the first 50 patients in the investigator-initiated SIBERIA trial that the company presented. Patients treated with CGuard™ EPS had a significantly lower incidence of multiple lesions in the brain (16% vs 44%), large cerebral lesions (24% vs 40%) and major adverse clinical events after 30 days (0% vs 12%) as compared to patients treated with a conventional open-cell carotid stent.

Read the analysts review, look at the market for NSPR products in this research report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/inspiremd/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source

View source version on accesswire.com: